The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries.

Trial Profile

The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2015

At a glance

  • Drugs Zotarolimus (Primary) ; Paclitaxel
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms RESOLUTE-Japan
  • Sponsors Medtronic
  • Most Recent Events

    • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 26 Jul 2011 1-Year results were presented at the 20th Annual Meeting of the Cardiovascular Intervention and Therapeutics (CVIT-2011).
    • 26 Jul 2011 Primary endpoint 'Late-loss' has been met (for noninferiority and superiority).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top